Jerry McMahon
Company: STORM Therapeutics Ltd.
Job title: President & Chief Executive Officer
Seminars:
Panel Discussion: Building Strategic Collaborations & Investment Pathways to Accelerate RNA-Targeted Drug Discovery Across Biotech & Pharma 9:00 am
• Discussing the importance of pharma-biotech-academic collaborations and what each sector can provide to successfully create RNA-targeted therapeutics • How are large pharma and biotech companies structuring risk-sharing partnerships to access innovation and accelerate RNA-targeted therapeutic pipelines • How can early-stage companies leverage academic collaborations, tool compound sharing and co development deals to validate targets…Read more
day: Conference Day Two
Advancing the Therapeutic Potential of Epitranscriptomics: Storm’s Firstin- Class METTL3 Inhibitor, STC-15 9:45 am
• Preclinical data demonstrates that modulating RNA methylation via METTL3 inhibition can enhance tumor sensitivity to treatment and impair resistance mechanisms • Epitranscriptomic regulation produces durable changes to gene expression and the tumor microenvironment, suggesting anti-cancer efficacy through multiple mechanisms • STC-15 clinical and translational data point to broad utility of METTL3 inhibition, enabling new…Read more
day: Conference Day Two